Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Healthy Participants: early-phase trial registry
42 of 120 indexed Healthy Participants trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #104 of 28,707 conditions by registered trial count.
120 US clinical trials · 42 currently recruiting · #104 of 28,707 conditions by registered trial count
Healthy Participants: 120 US clinical trials tracked, 42 recruiting.
Healthy Participants is the subject of 120 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 100 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 18 of these trials.
Enrollment posture brief
Registry condition healthy-participants
OPEN 42 | RECR 35% | LATE 1 | EARLY 100 | RANK #104 | SPON 18
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IIIA Breast Cancer AJCC v8 (35% recruiting · 40 trials)
Healthy Participants lists 42 open slots (35% of 120 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Healthy Participants on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Healthy Participants is recruiting below its size-band peers.
42 of 120 indexed trials (35%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Healthy Participants research.
AstraZeneca accounts for 18 of 120 trials (15%). 54 distinct sponsors appear on at least one study for this condition label.
-
Most Healthy Participants trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 120 trials that report a genuine target (sentinel values excluded). 96 of those (80%) plan for fewer than 100 participants.
-
Healthy Participants research is mostly interventional.
116 interventional and 4 observational studies make up this index (96.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
120 total, page 1 of 3
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Amgen
NCT07422285
Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort
Novozymes A/S
NCT07163637
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
Genentech
NCT07214766
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
Pfizer
NCT07122986
Sparking Potential, Revealing Infant Neurocognitive Traits
University of Wisconsin, Madison
NCT07390136
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
AstraZeneca
NCT07290283
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
AstraZeneca
NCT06980428
Effects of PeptiSleep on Sleep Quality in Healthy Adults
Nuritas
NCT07258433
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Pfizer
NCT06564389
Cognitive Strategies in Early Psychosis 1
University of Minnesota
NCT07231497
A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine
Cidara Therapeutics
NCT07300085
Biomarkers Study in Infants With Prior Neonatal Brain Injury
University of Wisconsin, Madison
NCT07413900
Cognition and Ultrasound
University of Minnesota
NCT07220655
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
Shionogi
NCT07093580
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
Kymera Therapeutics
NCT07412288
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
AstraZeneca
NCT07013643
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
Neurosterix
NCT07344948
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
Incyte Corporation
NCT07448155
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
AstraZeneca
NCT07455825
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
Trevi Therapeutics
NCT07487740
Researching Economical Adjuvants to Cancer Therapy
Florida State University
NCT07305259
Pistachio Snacking and Metabolic Flexibility
University of South Carolina
NCT07340125
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
Incyte Corporation
NCT06909162
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Eli Lilly and Company
NCT06916143
Fructose Intestinal Gluconeogenesis
Touro University, California
NCT07209202
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels
AstraZeneca
NCT07423598
The Increasing Mindfulness Engagement Project
Florida State University
NCT07170202
CanCan Body Composition Study
Pennington Biomedical Research Center
NCT07305753
Royal Ancient Oats™ Study
Standard Process
NCT07371598
A Study of Oral E1018 in Healthy Adult Participants
Eisai
NCT06854042
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Equilibra Bioscience
NCT06349473
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
Angitia Incorporated Limited
NCT07361354
Temporal Interference for Thalamocortical Activity and Network Modulation
University of Wisconsin, Madison
NCT07219719
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
AstraZeneca
NCT07404137
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
Invicro
NCT07348276
Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.
Ball State University
NCT07045051
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
Agios Pharmaceuticals
NCT07075640
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
Johns Hopkins University
NCT07224074
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
Ball State University
NCT07095426
A Study of Elenestinib in Healthy Adult Female Participants
Blueprint Medicines Corporation
NCT07388511
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
UCB Biopharma SRL
NCT06961747
Testing a Non-Invasive Spinal Stimulation Device
Gail Forrest
NCT07217314
A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388
Cidara Therapeutics
NCT07225959
A Study of LY4060874 in Healthy Participants
Eli Lilly and Company
NCT06709820
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
AstraZeneca
NCT06132841
A Phase I Study of CDX-622
Celldex Therapeutics
NCT06650761
Effect of Low Volume Sprint Interval Training on Cardiorespiratory Fitness
California State University, San Marcos
NCT07328568
A Study of STAR-0310 in Healthy Adult Participants
Astria Therapeutics
NCT06782477
Massage: Neuroimaging and Correlates of Response - 1-week Study
University of Utah
NCT07190313
A Study of LY4064809 in Healthy Adult Participants
Eli Lilly and Company
NCT07339735
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Healthy Participants records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Healthy Participants trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Healthy Participants page
120 registered trials, 42 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 42 Healthy Participants trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Healthy Participants trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Healthy Participants condition card totals 120 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.